MNPR 8-K: Press Release Attached for Quarter Ended June 30, 2025

Rhea-AI Filing Summary

Monopar Therapeutics Inc. (MNPR) filed an 8-K reporting that on August 12, 2025 the company issued a press release announcing its financial results for the quarter ended June 30, 2025. The press release is attached to the report as Exhibit 99.1. The filing also lists an Inline XBRL cover page as Exhibit 104, and provides the company headquarters in Wilmette, Illinois and Nasdaq listing information.

The 8-K explicitly states the Item 2.02 disclosure and the exhibit are being furnished, not filed, and therefore are not subject to Section 18 liability or incorporation by reference except as expressly stated in another filing. The report is signed by Quan Vu, Chief Financial Officer, dated August 12, 2025. The filing text does not include the press release content or numeric financial results.

Positive

• Press release announcing Q2 2025 financial results is attached as Exhibit 99.1, providing a formal disclosure channel
• Furnished, not filed designation is stated, clarifying Section 18 liability and incorporation scope

Negative

• The 8-K text does not include any financial figures or results, so the filing alone does not allow assessment of company performance
• Insufficient detail in the filing to determine material impact on financial condition or operations without reviewing Exhibit 99.1

Insights

Securities Analyst

TL;DR: Filing furnishes a Q2 2025 results press release; the 8-K itself contains no numeric results, so financial impact cannot be judged from this filing alone.

The 8-K notifies the market that Monopar issued a press release for the quarter ended June 30, 2025 and attaches it as Exhibit 99.1, while explicitly stating the exhibit is furnished, not filed. Because the filing does not include the press release text or financial figures, there is insufficient information here to determine revenue, earnings, or other performance metrics. Review of Exhibit 99.1 is required to assess material financial impact.

Corporate Governance Expert

TL;DR: The 8-K follows standard disclosure practice, listing exhibits and asserting furnished status; signature by the CFO indicates appropriate officer attestation.

The report includes required exhibit references (Exhibit 99.1 and 104) and a signature from Chief Financial Officer Quan Vu dated August 12, 2025, indicating procedural compliance with reporting rules. The explicit statement that the information is furnished and not filed limits Section 18 liability and clarifies incorporation by reference. No governance or control changes are described in the filing text.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0001645469 0001645469 2025-08-12 2025-08-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 12, 2025

MONOPAR THERAPEUTICS INC.

(Exact name of registrant as specified in its charter)

Delaware		001-39070		32-0463781
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

1000 Skokie Blvd., Suite 350, Wilmette, IL		60091
(Address of principal executive offices)		(Zip Code)

(847) 388-0349

Registrant’s telephone number, including area code

N/A

(Former name or former address, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value		MNPR		The Nasdaq Stock Market LLC (Nasdaq Capital Market)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition

On August 12, 2025, Monopar Therapeutics Inc. ("Monopar" or the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2025. A copy of this press release is attached hereto as Exhibit 99.1.

The information in this Item 2.02 and the exhibit hereto are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits

Exhibit No.		Description
99.1		Press Release Dated August 12, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Monopar Therapeutics Inc.
Date: August 12, 2025	By:	/s/ Quan Vu
	Name:	Quan Vu
	Title:	Chief Financial Officer

FAQ

What did Monopar (MNPR) disclose in this 8-K?

Monopar disclosed that it issued a press release on August 12, 2025 announcing financial results for the quarter ended June 30, 2025, and attached that press release as Exhibit 99.1.

Does the 8-K include Monopar's financial results numbers?

No. The filing text does not contain numeric financial figures; the press release attached as Exhibit 99.1 contains the announced results.

Was the press release furnished or filed with the SEC?

The filing states the press release and related information are furnished, not filed, and thus are not subject to Section 18 of the Exchange Act.

Who signed the 8-K for Monopar?

Quan Vu, Chief Financial Officer, signed the report on August 12, 2025.

Where is Monopar's principal executive office listed in the filing?

1000 Skokie Blvd., Suite 350, Wilmette, IL 60091 is provided as the principal executive office address.